Current management of alcoholic liver disease
https://doi.org/10.23946/2500-0764-2019-4-2-78-83
Abstract
In Russia, liver diseases largely contribute to the mortality. Here we review the literature on current management of alcoholic liver disease, which remains the leading cause of cirrhosis worldwide. The main risk factors for alcoholic liver disease are intake > 40 g and > 30 g of ethanol per day respectively for men and women, genetic predisposition, and obesity. Diagnosis is conventionally made on establishing of alcohol use disorder (AUDIT questionnaire). The main clinical forms of alcoholic liver disease are steatosis, hepatitis, and cirrhosis which can be discriminated by a panel of instrumental and laboratory investigations. The severity of alcoholic hepatitis is reflected by Maddrey discriminant function > 32 and MELD (Model for End-Stage Renal Disease) index > 20. Treatment of alcoholic liver disease considerably depends on abstinence and proper nutrition. In the absence of contraindications and insufficient efficiency of standard treatment, corticosteroids may be applied. Hepatoprotective drugs might also be efficient at various disease stages.
About the Authors
V. V. Tsukanov
Krasnoyarsk Science Center ofthe Siberian Branch ofRussian Academy ofSciences, Research Institute ofMedical Problems of the North
Russian Federation
Russian Federation
Prof. Vladislav V. Tsukanov - MD, DSc, Professor, Head of Digestive Diseases Unit, Krasnoyarsk Science Center ofthe Siberian Branch ofRussian Academy ofSciences
3G, Partisana Zheleznyaka Street, Krasnoyarsk, 660022A. V. Vasyutin
Krasnoyarsk Science Center ofthe Siberian Branch ofRussian Academy ofSciences, Research Institute ofMedical Problems of the North
Russian Federation
Russian Federation
Dr. Alexander V. Vasyutin - MD, PhD, Senior Researcher, Digestive Diseases Unit, Krasnoyarsk Science Center ofthe Siberian Branch ofRussian Academy ofSciences.
3G, Partisana Zheleznyaka Street, Krasnoyarsk, 660022
Y. L. Tonkikh
Krasnoyarsk Science Center ofthe Siberian Branch ofRussian Academy ofSciences, Research Institute ofMedical Problems of the North
Russian Federation
Russian Federation
Dr. Juliya L. Tonkikh - MD, PhD, Leading Researcher, Digestive Diseases Unit, Krasnoyarsk Science Center of the Siberian Branch ofRussian Academy ofSciences.
3G, Partisana Zheleznyaka Street, Krasnoyarsk, 660022
References
1. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline:Alcoholic Liver Disease.Am J Gastroenterol. 2018; 113 (2): 175-194. doi: 10.1038/ajg.2017.469.
2. Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69 (3): 718-735. doi: 10.1016/j.jhep.2018.05.011.
3. Tsukanov VV, Vasyutin AV, Tonkikh JL, Onuchina EV, Petrunko IL, Rzhavicheva OS, et al. The Burden of Hepatic Pathologies in the Modern World. Some Quality Parameters of Management of Patients with Liver Cirrhosis in the Siberian Federal District. Doctor.Ru. 2019; 3 (158): 6-10. Russian doi: 10.31550/1727-2378-2019-158-3-6-10.
4. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019; 70 (1): 151-171. doi: 10.1016/j.jhep.2018.09.014.
5. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010; 51 (1): 307-328. doi: 10.1002/hep.23258.
6. Sato N, Lindros КО, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res. 2001; 25 (5 Suppl ISBRA): 40S-45S.
7. You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019; 70 (2): 237-248. doi: 10.1016/j.jhep.2018.10.037.
8. Ivashkin VT, Mayevskaya MV, Pavlov ChS, Sivolap YuP, Lunkov VD, Zharkova MS, et al. Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society. Russian Journal of Gastroenterology, Hepatology, and Coloproctology. 2017; 27 (6): 20-40. Russian
9. Lucey MR, Mathurin Р, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009; 360 (26): 2758-2769. doi: 10.1056/NEJMra0805786.
10. Rugge M, Genta RM, Graham DY, Di Mario F, Vaz Coelho LG, Kim N, et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut. 2016; 65 (5): 721-725. doi: 10.1136/gutjnl-2015-310846.
11. Tsukanov VV, Amelchugova OS, Kasparov EV, Vasyutin AV, Tonkikh YuL, Tretyakova OV, et al. Role of Helicobacter pylori eradication in the prevention of gastric cancer. Therapeutic Archive. 2014; 86 (8): 124-127. Russian
12. Mathurin Р, Hadengue A, Bataller R, Addolorato G, Burra P, Burt A, et al. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012; 57 (2): 399-420. doi: 10.1016/j.jhep.2012.04.004.
13. Cabre E, Rodrfguez-Iglesias P, Caballerfa J, Quer JC, Sanchez-Lombrana JL, Pares A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology. 2000; 32 (1): 36-42. doi: 10.1053/jhep.2000.8627.
14. Gholam PM. Prognosis and prognostic scoring models for alcoholic liver disease and acute alcoholic hepatitis. Clin Liver Dis. 2016; 20 (3): 491-497. doi: 10.1016/j.cld.2016.02.007.
15. Thursz MR, Forrest EH, Ryder S; STOPAH investigators. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 373 (3): 282-283. doi: 10.1056/NEJMcl506342.
16. Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: metaanalysis of individual patient data. Gut. 2011; 60 (2): 255-260. doi: 10.1136/gut.2010.224097.
17. Gustot T, Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. J Hepatol. 2019; 70 (2): 319327. doi: 10.1016/j.jhep.2018.12.008.
18. Bataller R, Arteel GE, Moreno C, Shah V. Alcohol-related liver disease: Time for action. J Hepatol. 2019; 70 (2): 221-222. doi: 10.1016/j.jhep.2018.12.007.
Review
For citations:
Tsukanov V.V., Vasyutin A.V., Tonkikh Y.L. Current management of alcoholic liver disease. Fundamental and Clinical Medicine. 2019;4(2):78-83. (In Russ.) https://doi.org/10.23946/2500-0764-2019-4-2-78-83
Views:
465
Email this article 